RESUMEN
Severe leukopenia was incidentally found in a newborn Japanese Black calf by blood testing during the clinical trial of an iron dextran drug (day 1). At that time, no clinical problems were observed. On day 15, the calf presented with a high rectal temperature and tachypnea. Treatment with antibiotics and non-steroidal anti-inflammatory drugs did not improve clinical signs. Anemia, melena, and prolonged bleeding were also recorded. Necropsy findings revealed subcutaneous petechial hemorrhage and severe bone marrow aplasia. This is the first confirmed case of pancytopenia and hemorrhage associated with bone marrow aplasia in a Japanese Black calf.
Asunto(s)
Anemia Aplásica/veterinaria , Enfermedades de la Médula Ósea/veterinaria , Enfermedades de los Bovinos/congénito , Hemorragia/veterinaria , Pancitopenia/veterinaria , Anemia Aplásica/complicaciones , Animales , Enfermedades de la Médula Ósea/congénito , Enfermedades de la Médula Ósea/patología , Bovinos , Enfermedades de los Bovinos/etiología , Hemorragia/complicaciones , Pancitopenia/congénitoRESUMEN
The purpose of this study was to determine the pharmacokinetics and dose proportionality of mosapride citrate, a selective 5-HT4 agonist, after oral administration in horses. Seven healthy Thoroughbreds were dosed with distilled water and 0.5, 1.0, or 1.5 mg/kg mosapride citrate through a nasogastric tube. Serum mosapride concentrations were measured by a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Mosapride showed the Cmaxs of 31, 60, and 104 ng/g and AUCs of 178, 357, and 566 ng.hr/g at doses of 0.5, 1.0, 1.5 mg/kg, respectively. The Cmaxs and AUCs increased in proportion to the dose, indicating linear pharmacokinetics of mosapride up to 1.5 mg/kg. The pharmacokinetic profiles of mosapride in horses are quite different from that in humans. The average t1/2 in horses was almost 2 fold longer than that reported in healthy adult humans. Therefore, it is thought that it is suitable to reduce the number of doses a day in horses compared to humans.
Asunto(s)
Benzamidas/farmacocinética , Fármacos Gastrointestinales/farmacocinética , Morfolinas/farmacocinética , Administración Oral , Animales , Área Bajo la Curva , Benzamidas/administración & dosificación , Benzamidas/sangre , Relación Dosis-Respuesta a Droga , Femenino , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/sangre , Semivida , Caballos , Cinética , Masculino , Morfolinas/administración & dosificación , Morfolinas/sangre , Orquiectomía/veterinariaRESUMEN
The prokinetic effect of the 5-HT4 receptor agonist mosapride was evaluated in seven healthy thoroughbreds. Mosapride was orally administered at doses of 0.5, 1.0 or 1.5 mg/kg. The breath 13CO2/12CO2 rate (Delta13CO2), an indirect indicator for the rate of gastric emptying, was measured at appropriate points for 4 hr after drug administration. There was a significant increase compared with the control value at 15, 20 and 165 min for 0.5 mg/kg, 30 min at 1.0 mg/kg and 165 min for 1.5 mg/kg. The results suggest that mosapride may facilitate the gastric emptying in horses.